THBD and COVID-19: Various studies have reported heightened procoagulant activity in COVID-19 patients, characterized by elevated plasma levels of soluble thrombomodulin, indicative of enhanced endothelial cell activation, augmented fibrin formation, and increased resistance to fibrinolysis.